ETFs Holding CBMG »    CBMG Historical Stock Prices »
CBMG News Video: Tue, Jan 2, 2018, 2:38 PM — Tuesday Sector Leaders: Non-Precious Metals & Non-Metallic Mining, Biotechnology Stocks

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cellular Biomedicine is a biomedicine company, principally engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Co.'s technology includes two main cell platforms: Immune Cell therapy for treatment of a range of cancers using Chimeric Antigen Receptor modified T cells (CAR-T), T-Cell Receptor (TCR), cancer vaccine, and ex vivo expanded autologous Central Memory T Cells (Tcm); and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. Co. is conducting clinical studies in China with its stem cell based therapies to treat knee osteoarthritis. Self directed investors in Cellular Biomedicine Group Inc will be interested in keeping up with all Cellular Biomedicine Group Inc news they can find, both CBMG news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on CBMG. At RediNews, we simplify this task by presenting both CBMG news releases originating from Cellular Biomedicine Group Inc itself, and CBMG news from a variety of media outlets. Visitors can browse this news online and through our CBMG RSS news feed.


CBMG News — Articles, Videos, & Press Releases

IWV's Underlying Holdings Imply 11% Gain Potential
Friday, May 10, 2019, 8:26 AM — ETF Channel
We Did The Math VTWO Can Go To $142
Friday, April 5, 2019, 8:12 AM — ETF Channel
Commit To Buy Cellular Biomedicine Group At $10, Earn 18% Annualized Using Options
Monday, April 1, 2019, 11:44 AM — Stock Options Channel
Investors Grab CBMG 5.8% Cheaper Than Its Secondary Stock Offering
Monday, March 25, 2019, 11:14 AM — Dividend Channel
Cellular Biomedicine Group Shares Cross Below 200 DMA
Tuesday, March 12, 2019, 4:32 PM — Market News Video
Cellular Biomedicine Group (CBMG) Shares Cross Above 200 DMA
Thursday, February 14, 2019, 4:44 PM — Market News Video
Peek Under The Hood: PZI Has 23% Upside
Wednesday, February 6, 2019, 7:48 AM — ETF Channel
Peek Under The Hood: DWAS Has 43% Upside
Thursday, December 20, 2018, 7:58 AM — ETF Channel
DWAS's Holdings Could Mean 29% Gain Potential
Wednesday, November 14, 2018, 8:28 AM — ETF Channel
Relative Strength Alert For Cellular Biomedicine Group
Tuesday, October 23, 2018, 1:13 PM — Dividend Channel
How The Parts Add Up: DWAS Headed For $62
Friday, October 5, 2018, 7:47 AM — ETF Channel
Commit To Buy Cellular Biomedicine Group At $15, Earn 26% Annualized Using Options
Tuesday, October 2, 2018, 11:48 AM — Stock Options Channel
CBMG is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

APT News

RediNews invites financial news content websites to integrate our XML content for web sites by integrating our RSS feeds found throughout our website wherever news and stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic content is ideal for any financial portal or web portal, from business content web sites to corporate portal intranets. Let RediNews be your content provider of free financial content for news, perfect for location on stock market chart pages by symbol, adding another element of dynamic stock market content to your financial portal. If your web page content already includes elements like SEC filings, screener pages, historical chart information, and other cobranded financial web content, then headlines from RediNews can supplement this dynamic financial content meaningfully.

CBMG News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.